These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37513579)

  • 21. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
    Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
    Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
    Ogata H; Takeshima A; Ito H
    Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphate balance during dialysis and after kidney transplantation in patients with chronic kidney disease.
    Duque EJ; Elias RM; Moysés RMA
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):326-331. PubMed ID: 35703226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.
    Imtiaz R; Hawken S; McCormick BB; Leung S; Hiremath S; Zimmerman DL
    Nutrients; 2017 Feb; 9(2):. PubMed ID: 28218647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
    Dong J; Wang H; Wang M
    J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
    Sherman RA
    Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
    Galassi A; Cupisti A; Santoro A; Cozzolino M
    J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations.
    Cozzolino M; Ketteler M; Wagner CA
    Expert Opin Ther Targets; 2020 May; 24(5):477-488. PubMed ID: 32191548
    [No Abstract]   [Full Text] [Related]  

  • 30. [The contribution of dialysis and laboratoristic methods for the control of phosphates].
    Bolasco P
    G Ital Nefrol; 2014; 31(2):. PubMed ID: 24777923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
    Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
    Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Pilot Study of OkKidney, a Phosphate Counting Application in Patients on Peritoneal Dialysis.
    Imtiaz R; Atkinson K; Guerinet J; Wilson K; Leidecker J; Zimmerman D
    Perit Dial Int; 2017; 37(6):613-618. PubMed ID: 28970367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in Adults Undergoing Maintenance Hemodialysis: A Systematic Review and Meta-Analysis.
    St-Jules DE; Rozga MR; Handu D; Carrero JJ
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):107-120. PubMed ID: 33380474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
    Lenglet A; Liabeuf S; Guffroy P; Fournier A; Brazier M; Massy ZA
    Drugs R D; 2013 Sep; 13(3):165-73. PubMed ID: 24000048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phosphate binders].
    Heeb RM
    Med Monatsschr Pharm; 2016 Jun; 39(6):255-60. PubMed ID: 27439258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics.
    Badve SV; Zimmerman DL; Knoll GA; Burns KD; McCormick BB
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1711-7. PubMed ID: 18815242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dialytic phosphate removal: a modifiable measure of dialysis efficacy in automated peritoneal dialysis.
    Schmitt CP; Borzych D; Nau B; Wühl E; Zurowska A; Schaefer F
    Perit Dial Int; 2009; 29(4):465-71. PubMed ID: 19602613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosocial Factors That Create Barriers to Managing Serum Phosphorus Levels in Pediatric Dialysis Patients: A Retrospective Analysis.
    Taylor JM; Oladitan L; Degnan A; Henderson S; Dai H; Warady BA
    J Ren Nutr; 2016 Jul; 26(4):270-5. PubMed ID: 26993357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.